WO2021133171A1 - Cellule fongique recombinante - Google Patents

Cellule fongique recombinante Download PDF

Info

Publication number
WO2021133171A1
WO2021133171A1 PCT/NL2020/050818 NL2020050818W WO2021133171A1 WO 2021133171 A1 WO2021133171 A1 WO 2021133171A1 NL 2020050818 W NL2020050818 W NL 2020050818W WO 2021133171 A1 WO2021133171 A1 WO 2021133171A1
Authority
WO
WIPO (PCT)
Prior art keywords
fungal cell
squalene
tetrahymanol
protein
recombinant fungal
Prior art date
Application number
PCT/NL2020/050818
Other languages
English (en)
Inventor
Jacobus Thomas Pronk
Sanne Jitske WIERSMA
Wijbrand Joannes Cornelis DEKKER
Jonna BOUWKNEGT
Original Assignee
Technische Universiteit Delft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2024578A external-priority patent/NL2024578B1/en
Application filed by Technische Universiteit Delft filed Critical Technische Universiteit Delft
Publication of WO2021133171A1 publication Critical patent/WO2021133171A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P15/00—Preparation of compounds containing at least three condensed carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01123—Tetrahymanol synthase (4.2.1.123)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01129—Squalene--hopanol cyclase (4.2.1.129)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y504/00—Intramolecular transferases (5.4)
    • C12Y504/99—Intramolecular transferases (5.4) transferring other groups (5.4.99)
    • C12Y504/99017—Squalene--hopene cyclase (5.4.99.17)

Definitions

  • the invention relates to a recombinant fungal cell.
  • the invention further relates to a culturing method.
  • the invention further relates to a production method.
  • the invention further relates to a growth medium.
  • the invention further relates to a use of the recombinant fungal cell.
  • US20030207317A1 describes nucleic acids isolated from Tetrahymena which code for a ciliate-specific triterpenoid cyclase, and describes the use of nucleic acids for the regulation of triterpenoid cyclase expression in a host organism, as well as the targeted knockout or repriming of the triterpenoid cyclase gene.
  • EP3042960Al describes a method for producing ambrein, comprising reacting a tetraprenyl-P-curcumene cyclase with 3- deoxyachilleol A to obtain ambrein.
  • W02018157021A1 describes a squalene hopene cyclase isolated from Gluconobacter morbifer as well as variants thereof and a method for using the G. morbifer SHC to biocatalytically convert homofamesol to ambroxan.
  • Saccharomyces yeasts have a long history in anaerobic biotechnology. Already, S. cerevisiae may be responsible for what may be the single largest product of modern industrial biotechnology: (‘bio’-)ethanol as an automotive biofuel. The world-wide production of this yeast fermentation product, which may predominantly be made from com starch and cane sugar, may currently be ca. 65 million tonnes/year. Concerns about competition with food and feed production may provide strong incentives for development of production processes for desired products, such as ethanol, from non-food agricultural residues and energy crops.
  • Saccharomyces species may be rare among yeasts and, indeed, among fungi, for their ability to grow (well) in the absence of molecular oxygen.
  • Saccharomyces species may need supplemented growth media to support anaerobic growth, or may otherwise rely on intracellular sterol accumulated during an aerobic precultivation phase and/or natural sterol contents of plant-biomass-based industrial growth media. Supplemented growth media for anaerobic growth may be more complex than media used for aerobic growth, which may be disadvantageous with regards to medium preparation.
  • Supplementation as well as reliance on cellular sterol reserves or sterol contents of industrial plant-biomass-based media can also negatively affect predictability and reproducibility of growth outcomes. Further, the supplements may add additional costs to the media preparation, which may be particularly disadvantageous for the production of bulk chemicals, such as ethanol.
  • fungi including many yeasts, such as the facultatively fermentative yeast species Hansenula (Ogataea) polymorpha and Kluyveromyces marxianus, may not grow (well) anaerobically in these supplemented growth media.
  • yeasts such as the facultatively fermentative yeast species Hansenula (Ogataea) polymorpha and Kluyveromyces marxianus
  • These fungi may include species with industrially highly attractive properties, such as thermotolerance, broad substrate specificity and robustness to inhibitors present in plant biomass hydrolysates, but prior art strains may be unsuitable for simple, low-cost anaerobic processes.
  • the (non-respiratory) requirements for molecular oxygen may also be adverse in industrial production processes under (micro-)oxic conditions. Specifically, aeration of bioreactors to provide a sufficient level of dissolved oxygen may be energy-demanding and expensive, and the required level of dissolved oxygen may at least partially be due to the (non- respiratory) need for molecular oxygen.
  • the present invention may have as object to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.
  • the invention may provide a recombinant fungal cell comprising at least one genome modification relative to a parental fungal cell.
  • the genome modification may especially comprise (an insertion of) an exogenous gene.
  • the exogenous gene may provide the recombinant fungal cell with the ability to synthesize a (suitable) sterol surrogate under anaerobic conditions.
  • the exogenous gene may encode a protein selected from the group comprising a protein having squalene- tetrahymanol cyclase activity and a protein having squalene-hopene cyclase activity.
  • a recombinant Saccharomyces cerevisiae cell expressing a gene encoding a squalene-tetrahymanol cyclase may grow anaerobically without sterol supplements.
  • a recombinant Saccharomyces cerevisiae cell expressing a gene encoding a squalene-hopene cyclase may grow anaerobically without sterol supplements.
  • a recombinant Kluyveromyces marxianus cell expressing a gene encoding a squalene-tetrahymanol cyclase may grow anaerobically, even though Kluyveromyces marxianus may not grow anaerobically even in a growth medium supplemented with sterols.
  • Sterols are a class of hydrophobic triterpenoid compounds, representatives of which may be important constituents in almost all eukaryotic membranes. Sterols may affect membrane fluidity and permeability as well as localization of specific membrane proteins. In particular, ergosterol may be the major sterol in most fungi. In aerobic conditions, S. cerevisiae may synthesize ergosterol from squalene in a multi -reaction process, which may consume 12 molecules of molecular oxygen for each molecule of ergosterol produced. Given the need for molecular oxygen, S. cerevisiae may not produce ergosterol in anoxic conditions.
  • anoxic conditions may herein especially refer to conditions wherein the oxygen concentration is below a detection threshold.
  • the term “anoxic conditions” may refer to conditions wherein the available oxygen is insufficient for a parental S. cerevisiae cell to grow in the absence of sterol supplementation.
  • the growth media for S. cerevisiae may be supplemented with ergosterol - or with one or more other sterols - to facilitate anaerobic growth.
  • S. cerevisiae may incorporate one or more sterols from the supplemented growth medium in order to grow anaerobically.
  • S. cerevisiae has been intensively used as a model organism for studying in vivo eukaryotic sterol function and biosynthesis.
  • Sterol synthesis mutants of S. cerevisiae have revealed a wide range of cellular processes impacted by sterol content and composition, which may include endocytosis, intracellular trafficking and excretion of proteins and nutrient uptake.
  • sterols may affect resistance to external stresses. Consistent with the importance of sterols for fungal growth, many fungicides may target ergosterol biosynthesis.
  • trace (‘sparking’) amounts of specific sterols may include, for example: Rodriguez et al. 1982; Pinto and Nes 1983; Lorenz et al. 1989; and Nes et al. 1993.
  • the invention may provide a recombinant fungal cell comprising at least one genome modification relative to a parental fungal cell (also: “parent fungal cell”).
  • a parental fungal cell also: “parent fungal cell”.
  • the recombinant fungal cell may be derived from the parental fungal cell.
  • the term “parental fungal cell” may herein also refer to a plurality of parental fungal cells (of a parental fungal strain), especially to the parental fungal strain.
  • recombinant fungal cell may refer herein to a fungal cell comprising at least one genome modification, especially relative to a (corresponding) parental fungal cell.
  • the recombinant fungal cell may especially be a yeast cell.
  • the recombinant fungal cell may especially be a filamentous fungus cell, i.e. a cell of a filamentous fungus.
  • the term “recombinant fungal cell” may herein also refer to a plurality of recombinant fungal cells (of a recombinant fungal strain), especially to the recombinant fungal strain.
  • genome modification may be used herein to refer to a difference between two genomes, especially wherein the difference was deliberately introduced.
  • the genome modification may comprise one or more of an insertion (also “addition”), a deletion and a substitution (of nucleotides).
  • the genome modification may especially comprise an exogenous gene, i.e., especially an insertion of an exogenous gene.
  • the term “genome modification” may also refer to a plurality of genome modifications.
  • the parental fungal cell may be incapable of anaerobic growth.
  • the parental fungal cell may be auxotrophic for sterols in anoxic conditions, especially for one or more specific sterols (see above), or especially wherein any one sterol from a group of specific sterols is sufficient to complement the auxotrophy of the parental fungal cell.
  • auxotrophic may herein refer to the inability of an organism to synthesize a particular compound required for its growth.
  • the parental fungal cell may especially be selected from the group comprising
  • the parental fungal cell may especially be a yeast cell.
  • the recombinant fungal cell may especially be a filamentous fungus cell. It will be clear to the person skilled in the art that the parental fungal cell and the recombinant fungal cell will essentially be the same species.
  • the parental fungal cell may be selected from the group comprising Saccharomycetaceae, such as Saccharomyces cerevisiae, Saccharomyces pastorianus, Saccharomyces beticus, Saccharomyces fermentati, Saccharomyces paradoxus, Saccharomyces uvarum and Saccharomyces bayanus; Torulaspora, such as Torulaspora delbrueckii; Kluyveromyces, such as Kluyveromyces marxianus and Kluyveromyces lactis; Pichia, such as Pichia stipitis (also known as Scheffersomyces stipitis), Pichia pastoris; Ogataea, such as Ogataea parapolymorpha; Zygosaccharomyces, such as Zygosaccharomyces bailii; Brettanomyces, such as Brettanomyces intermedius, Brettanomyces bruxellensis, Brettanomyces anomalus
  • the parental fungal cell may be selected from the group comprising Schizosaccharomycetaceae, such as Schizosaccharomyces, such as Schizosaccharomyces pombe, Schizosaccharomyces japonicus, Schizosaccharomyces octosporus and Schizosaccharomyces cryophilus, especially selected from the group comprising Schizosaccharomyces pombe, Schizosaccharomyces octosporus and Schizosaccharomyces cryophilus; or from the group of Dothideomycetes, such as Aureobasidium pullulans ; or from the group of Dipodascaceae, such as Yarrowia lipolytica.
  • Schizosaccharomycetaceae such as Schizosaccharomyces, such as Schizosaccharomyces pombe, Schizosaccharomyces japonicus, Schizosaccharomyces octosporus and Schizos
  • the parental fungal cell may comprise a Saccharomycetaceae species. In further embodiments, the parental fungal cell may comprise a Schizosaccharomyces species. In further embodiments, the parental fungal cell may comprise a Torulaspora species. In further embodiments, the parental fungal cell may comprise a Kluyveromyces species. In further embodiments, the parental fungal cell may comprise a Pichia species. In further embodiments, the parental fungal cell may comprise an Ogataea species. In further embodiments, the parental fungal cell may comprise a Zygosaccharomyces species. In further embodiments, the parental fungal cell may comprise a Brettanomyces species.
  • the parental fungal cell may comprise a Metschnikowia species. In further embodiments, the parental fungal cell may comprise an Issatchenkia species. In further embodiments, the parental fungal cell may comprise a Kloeckera species. In further embodiments, the parental fungal cell may comprise an Aureobasidium species. In further embodiments, the parental fungal cell may comprise a Yarrowia species.
  • the recombinant fungal cell may be a yeast cell.
  • the recombinant fungal cell may be selected from the group comprising Saccharomycetaceae, such as Saccharomyces cerevisiae, Saccharomyces pastorianus, Saccharomyces eubayanus, Saccharomyces jurei, Saccharomyces beticus, Saccharomyces fermentati, Saccharomyces paradoxus, Saccharomyces uvarum and Saccharomyces bayanus; Torulaspora, such as Torulaspora delbrueckii; Kluyveromyces, such as Kluyveromyces marxianus and Kluyveromyces lactis; Pichia, such as Pichia stipitis (also known as Scheffersomyces stipitis), Pichia pastoris; Ogataea, such as Ogataea parapolymorpha; Zygosaccharomyces, such as Zygosaccharomyces bailii; Brettanomyces, such as Brettanomyces
  • the parental fungal cell may be selected from the group comprising Schizosaccharomycetaceae, such as Schizosaccharomyces, such as Schizosaccharomyces pombe, Schizosaccharomyces japonicus, Schizosaccharomyces octosporus and Schizosaccharomyces cryophilus, especially selected from the group comprising Schizosaccharomyces pombe, Schizosaccharomyces octosporus and Schizosaccharomyces cryophilus; or from the group of Dothideomycetes, such as Aureobasidium pullulans ; or from the group of Dipodascaceae, such as Yarrowia lipolytica.
  • Schizosaccharomycetaceae such as Schizosaccharomyces, such as Schizosaccharomyces pombe, Schizosaccharomyces japonicus, Schizosaccharomyces octosporus and Schizos
  • the recombinant fungal cell may be a (recombinant) filamentous fungus cell.
  • the fungal cell may be selected from the group comprising Aspergillus spp., Penicillium spp. and Trichoderma spp.
  • the parental fungal cell may be a filamentous fungus cell.
  • the parental fungal cell may be selected from the group comprising Aspergillus spp., Rhizopus spp., Myceliophthera spp., Thielavia spp., Penicillium spp. and Trichoderma spp.
  • the recombinant fungal cell and the parental fungal cell are the same species.
  • the recombinant fungal cell may be selected from the group comprising Saccharomyces and Kluyveromyces, especially from the group comprising Saccharomyces, such as the group comprising Saccharomyces cerevisiae, Saccharomyces pastorianus, Saccharomyces eubayanus, Saccharomyces jurei, Saccharomyces beticus, Saccharomyces fermentati, Saccharomyces paradoxus, Saccharomyces uvarum and Saccharomyces bayanus, or especially from the group comprising Kluyveromyces, such as the group comprising Kluyveromyces marxianus and Kluyveromyces lactis.
  • Saccharomyces such as the group comprising Saccharomyces cerevisiae, Saccharomyces pastorianus, Saccharomyces eubayanus, Saccharomyces jurei, Saccharomyces beticus, Saccharomyces fermentati, Saccharomyces paradoxus
  • the parental fungal cell may be selected from the group comprising Saccharomyces and Kluyveromyces, especially from the group comprising Saccharomyces, such as the group comprising Saccharomyces cerevisiae, Saccharomyces pastorianus, Saccharomyces eubayanus, Saccharomyces jurei, Saccharomyces beticus, Saccharomyces fermentati, Saccharomyces paradoxus, Saccharomyces uvarum and Saccharomyces bayanus, or especially from the group comprising Kluyveromyces, such as the group comprising Kluyveromyces marxianus and Kluyveromyces lactis
  • Saccharomyces such as the group comprising Saccharomyces cerevisiae, Saccharomyces pastorianus, Saccharomyces eubayanus, Saccharomyces jurei, Saccharomyces beticus, Saccharomyces fermentati, Saccharomyces paradoxus, Saccharomy
  • the invention is herein, for explanatory purposes, primarily described with respect to S. cerevisiae and K. marxianus. However, it will be clear to the person skilled in the art that the invention is not limited to S. cerevisiae and K. marxianus.
  • the genome modification may comprise an exogenous gene.
  • exogenous gene may herein especially refer to a gene exogenous to the parental fungal cell, especially to the parental fungal species.
  • the genome of the recombinant fungal species and the genome of the parental fungal cell may differ in at least that the genome of the recombinant fungal species comprises (an insertion of) the exogenous gene, wherein the exogenous gene is absent from the genome of the parental fungal cell, especially from the parental fungal species.
  • the exogenous gene may encode a protein having an activity, wherein the activity is absent from the proteins encoded by expressible native genes of the parental fungal cell.
  • the exogenous gene encodes a protein having squalene-tetrahymanol cyclase activity
  • the squalene-tetrahymanol cyclase activity may be absent from the proteins encoded by (expressible) native genes of the parental fungal cell, i.e., the parental fungal cell may (be selected to) lack a gene encoding a protein having the squalene-tetrahymanol cyclase activity.
  • the recombinant fungal cell may be configured to express the exogenous gene.
  • the recombinant fungal cell may be configured to transcribe the exogenous gene into (exogenous) mRNA, and especially to translate the (exogenous) mRNA into an (exogenous) protein. It will be clear to the person skilled in the art how to configure the recombinant fungal cell such that the exogenous gene is expressed.
  • the exogenous gene may, for example, be provided with or be arranged at a site providing a suitable promoter.
  • the exogenous gene may encode a protein, especially an exogenous protein, selected from the group comprising a protein having squalene- tetrahymanol cyclase activity and a protein having squalene-hopene cyclase activity.
  • the exogenous gene may encode a protein, especially an exogenous protein, having squalene-tetrahymanol cyclase activity.
  • the exogenous gene may encode a protein, especially an exogenous protein, having squalene-hopene cyclase activity.
  • a protein having activity such as in the phrase “a protein having squalene-tetrahymanol cyclase activity” may herein especially refer to the protein catalyzing the corresponding reaction, irrespective of whether the protein is annotated as a protein catalyzing the indicated reaction.
  • the activity may especially be inferred from the presence of the (direct) product of the reaction.
  • the activity may be inferred from the presence of the (direct) product of the reaction in a cell, or in a culture broth comprising the cell, expressing a gene encoding the protein, especially by comparing the quantity of the (direct) product with the quantity thereof in a second cell, or in a culture broth comprising the second cell, devoid of the gene (or not expressing it).
  • the activity of an exogenous protein having squalene-tetrahymanol cyclase activity may be inferred from the presence of tetrahymanol in a recombinant S. cerevisiae cell, wherein the recombinant S. cerevisiae cell expresses an exogenous gene encoding the exogenous protein.
  • the activity of an exogenous protein having squalene-hopene cyclase activity may be inferred from the presence of one or more hopanoids in a recombinant S.
  • an exogenous gene encoding the exogenous protein especially from the presence of one or more of hop-22(29)-ene, hopan-22-ol, hop- 17(21)-ene, hop-21-ene.
  • the activity of an exogenous protein having squalene-hopene cyclase activity may, for example, also be inferred from the presence of tetrahymanol in a fungus expressing a native or (second) exogenous gene encoding a protein having a tetrahymanol synthase (hopene) activity.
  • a protein having squalene-tetrahymanol cyclase activity may herein especially refer to a protein capable of catalyzing the reaction squalene + H 2 0 tetrahymanol
  • a protein having squalene-hopene cyclase activity may herein especially refer to a protein capable of catalyzing the reaction squalene hopene
  • the protein having squalene-hopene cyclase activity may especially be capable of catalyzing the reaction squalene hopene.
  • the protein having squalene-hopene cyclase activity may especially be capable of catalyzing the reaction squalene + H2O hopanol.
  • hopanoid may herein especially refer to a pentacyclic compound based on the chemical structure of hopane, especially wherein an outermost (E-)ring consists of 5 carbon atoms, and especially belonging to the class of cyclic triterpenoids and synthesized by cyclization of the branched terpenoid hydrocarbon squalene.
  • a protein having tetrahymanol synthase activity may herein especially refer to a protein capable of catalyzing the reaction hopene + H 2 0 tetrahymanol
  • the recombinant fungal cell may be capable of producing a desired product.
  • the term “desired product” may herein refer to a (bulk) chemical as defined below.
  • the desired product may also be biomass.
  • the invention may provide a recombinant fungal cell comprising at least one genome modification relative to a parental fungal cell, wherein the genome modification comprises an exogenous gene encoding a protein selected from the group comprising a protein having squalene-tetrahymanol cyclase activity and a protein having squalene-hopene cyclase activity.
  • the exogenous gene may encode the (exogenous) protein with squalene-tetrahymanol cyclase activity.
  • sequence identity refers to the percentage of the characters (such as amino acids for protein sequences) of two sequences matching in a sequence alignment (also see below) of the two sequences. The higher the sequence identity between two proteins, the higher the chance may be that these two proteins have the same or a similar function.
  • proteins may have been successfully annotated based on a common rule-of-thumb threshold of at least 30-40% sequence identity.
  • proteins comprising an amino acid sequence similar to a protein with known squalene-tetrahymanol cyclase activity may be likely to also have squalene-tetrahymanol cyclase activity.
  • the protein with squalene-tetrahymanol cyclase activity may have a first amino acid sequence, especially wherein the first amino acid sequence has a sequence identity of at least 30% with respect to a sequence alignment with a (first) reference amino acid sequence of a reference squalene-tetrahymanol cyclase, such as an amino acid identity of at least 40%, especially at least 50%, such as at least 60%, especially at least 70%, such as at least 80%, especially at least 90%, such as at least 95%, including 100%.
  • the sequence alignment may have a length of at least 30% of the (first) reference amino acid sequence, such as at least 40%, especially at least 50%, such as at least 60%, especially at least 70%, such as at least 80%, especially at least 90%, such as at least 95%, including 100%.
  • the reference squalene-tetrahymanol cyclase may be derived from an organism selected from the group comprising Neocallimastigomycota , Tetrahymena spp., and Oleandra spp..
  • a sequence alignment of two (or more) sequences may be obtained using, for example, BLASTp.
  • BLASTp is a Basic Local Alignment Search Tool for proteins and will be familiar to the person skilled in the art.
  • BLASTp may be used to align a query amino acid sequence against another amino acid sequence, especially with default settings, and may provide an alignment indicating the “query coverage” of the query amino acid sequence(s) (the percentage of the query amino acid sequence successfully aligned with the other amino acid sequence) and a sequence identity.
  • the phrase “a sequence alignment having a sequence length > 50% of the sequence length of a reference amino acid sequence” may especially refer to a “query coverage” of > 50% for a BLASTp alignment with the reference amino acid sequence as the query amino acid sequence.
  • two sequences may be aligned via BLASTp, especially using default algorithm parameters, such as using a BLOSUM62 matrix with a gap cost of 11 : 1 (existence:extension).
  • the exogenous gene may encode a protein with squalene- hopene cyclase activity.
  • the protein with squalene-hopene cyclase activity has a second amino acid sequence, wherein the second amino acid sequence has a sequence identity of at least 30% with respect to a sequence alignment with a (second) reference amino acid sequence of a reference squalene-hopene cyclase, such as an amino acid identity of at least 40%, especially at least 50%, such as at least 60%, especially at least 70%, such as at least 80%, especially at least 90%, such as at least 95%, including 100%.
  • sequence alignment may have a length of at least > 30% of the (second) reference amino acid sequence, such as at least 40%, especially at least 50%, such as at least 60%, especially at least 70%, such as at least 80%, especially at least 90%, such as at least 95%, including 100%.
  • the reference squalene-hopene cyclase may be derived from an organism selected from the group comprising Alicyclobacillus acidocaldarius, Zymomonas mobilis, Bradyrhizobium japonicum, Sinorhizobium fredii, Rhodopseudomonas palustris, Streptomyces peucetius, Methylococcus capsulatus, Schizosaccharomyces japonicus, Adiantum capillus, and Dryopteris crassirhizoma.
  • the exogenous gene may encode a protein with tetrahymanol synthase activity.
  • the protein with tetrahymanol synthase activity has a third amino acid sequence, wherein the third amino acid sequence has a sequence identity of at least 30% with respect to a sequence alignment with a (third) reference amino acid sequence of a reference tetrahymanol synthase, such as an amino acid identity of at least 40%, especially at least 50%, such as at least 60%, especially at least 70%, such as at least 80%, especially at least 90%, such as at least 95%, including 100%.
  • the sequence alignment may have a length of at least > 30% of the (third) reference amino acid sequence, such as at least 40%, especially at least 50%, such as at least 60%, especially at least 70%, such as at least 80%, especially at least 90%, such as at least 95%, including 100%.
  • the reference tetrahymanol synthase may be derived from an organism selected from the group comprising Methylomicrobium alcaliphilum, Bradyrhizobium japonicum, Rhodopseudomonas palustris, Nitrobacter hamburgensis, Afipia broomeae, Agromonas oligotrophica, Rhodovulum sp. PH 10, Methylobacterium nodulans, and Desulfovibrio africanus.
  • the genome modification may comprise a plurality of exogenous genes.
  • the exogenous gene may comprise one or more of a first exogenous gene, a second exogenous gene, and a third exogenous gene.
  • the first exogenous gene may especially encode a protein having squalene- tetrahymanol cyclase activity.
  • the second exogenous gene may especially encode a protein having squalene-hopene cyclase activity.
  • the third exogenous gene may especially encode a protein having tetrahymanol synthase activity.
  • the exogenous gene may comprise the second exogenous gene and the third exogenous gene.
  • the recombinant fungal cell may convert squalene to tetrahymanol via hopene.
  • the exogenous gene may encode a protein catalyzing a chemical reaction, wherein the protein enables the recombinant fungal cell to produce a sterol- surrogate in an oxygen-independent manner, especially a sterol-surrogate selected from the group comprising tetrahymanol and a hopanoid, wherein the parental fungal cell is incapable of producing the sterol-surrogate.
  • sterol-surrogate may herein especially refer to a compound suitable to compensate for a deficiency in one or more sterols in a fungus, especially in the recombinant fungal cell, especially suitable to compensate for a deficiency in all sterols in the fungus.
  • the recombinant fungal cell may comprise one or more compounds selected from the group comprising tetrahymanol and a hopanoid.
  • tetrahymanol and hopanoids can at least partially replace sterols in S. cerevisiae cells.
  • ergosterol a main sterol in fungi, may be found in lipid structures, such as cell membranes and/or lipid globules, of fungi.
  • the recombinant fungal cell may comprise a lipid structure, wherein the lipid structure comprises one or more compounds selected from the group comprising tetrahymanol and a hopanoid, especially tetrahymanol, or especially a hopanoid.
  • the lipid structure may comprise a membrane, especially an (outer) cell membrane.
  • the lipid structure may comprise a lipid globule.
  • the genome modification may further comprise a deletion of a squalene epoxidase gene, especially a deletion of all copies of a squalene epoxidase gene, more especially the deletion of all copies of all squalene epoxidase genes in the genome of the parental fungal cell.
  • Squalene epoxidase may generally catalyze the first oxygen-consuming reaction in sterol synthesis, thereby consuming squalene and providing oxidosqualene.
  • the recombinant fungal cell may be made incapable of sterol synthesis.
  • the recombinant fungal cell may have a more consistent performance, as access to small amounts of oxygen would not result in sterol synthesis, which could otherwise affect the cell membrane. Further, by preventing flux through the sterol synthesis pathway, the otherwise consumed molecular oxygen may remain available for other metabolic processes, thereby effectively reducing the need for molecular oxygen under (micro-)aerobic conditions.
  • the genome modification may result in changes in characteristics of the fungus.
  • the expression of a gene encoding a protein having squalene-tetrahymanol cyclase activity may result in an increased tolerance to high temperatures, which may be beneficial, especially in industrial settings.
  • S. cerevisiae may have a temperature optimum for growth and fermentation of about 30-35°C.
  • fungal enzymes typically used for hydrolysis of cellulose and other plant polymers may generally function optimally at temperatures above 50 °C. Therefore, especially for production of biofuels such as ethanol, n-butanol and isobutanol from agricultural residues, it may be attractive to perform fermentation processes at a higher temperature.
  • a high temperature during fermentation may reduce the need to cool hydrolysates prior to fermentation and may support simultaneous saccharification and fermentation strategies. Moreover, higher fermentation temperatures may decrease costs for product recovery by distillation and may reduce microbial contamination risks.
  • the invention may be particularly beneficial with regards to fungi naturally endowed with a (high) tolerance to high temperatures.
  • the recombinant fungal cell may both be tolerant to high temperatures and be capable of synthesizing a sterol- surrogate in an oxygen-independent manner.
  • the parental fungal cell may, for example, be a K. marxianus cell.
  • the recombinant fungal cell may comprise an exogenous gene encoding a protein having tetrahymanol synthase activity.
  • Such embodiments may be particularly beneficial with regards to recombinant fungal cells further comprising an exogenous gene encoding a protein having squalene-hopene cyclase activity, and/or with regards to a recombinant fungal cell derived from a parental fungal cell, wherein the parental fungal cell comprises an (expressible) native gene encoding a protein having squalene-hopene cyclase activity.
  • the recombinant fungal cell comprises at least one genome modification relative to a parental fungal cell, wherein the genome modification comprises an exogenous gene encoding a protein having tetrahymanol synthase activity, wherein: - the genome modification further comprises an exogenous gene encoding a protein having squalene-hopene cyclase activity; or wherein the parental fungal cell comprises an (expressible) native gene encoding a protein having squalene-hopene cyclase activity.
  • the parental fungal cell may be selected from the group comprising Aspergilli and Schizosaccharomyces, especially Schizosaccharomyces japonicus. These fungi may comprise an (expressible) native gene encoding a protein having squalene- hopene cyclase activity.
  • the invention may provide a culturing method for culturing a recombinant fungal cell according to any one of the preceding claims. The culturing method may comprise inoculating a growth medium with the recombinant fungal cell.
  • the recombinant fungal cell may be capable of producing a sterol- surrogate, such as tetrahymanol or a hopanoid, especially wherein the sterol-surrogate may at least partially compensate for a deficiency in one or more sterols, especially all sterols.
  • the recombinant fungal cell may be capable of producing the sterol-surrogate in microoxic and anoxic conditions, especially in anoxic conditions.
  • the growth medium may especially comprise ⁇ 5 mg/L of sterols, such as ⁇ 1 mg/L, especially ⁇ 0.1 mg/L, such as ⁇ 0.05 mg/L, especially ⁇ 0.01 mg/L, such as ⁇ 0.001 mg/L, including (essentially) no sterols.
  • sterols such as ⁇ 1 mg/L, especially ⁇ 0.1 mg/L, such as ⁇ 0.05 mg/L, especially ⁇ 0.01 mg/L, such as ⁇ 0.001 mg/L, including (essentially) no sterols.
  • the growth medium may, especially during at least part of the culturing method, comprise ⁇ 0.5 mg/L dissolved oxygen, such as ⁇ 0.3 mg/L, especially ⁇ 0.1 mg/L, such as ⁇ 0.05 mg/L dissolved oxygen, especially ⁇ 0.01 mg/L dissolved oxygen, such as ⁇ 0.001 mg/L dissolved oxygen, including (essentially) no dissolved oxygen.
  • the growth medium may be anoxic, especially during at least part of the culturing method.
  • the invention may provide a production method for producing a desired product using the recombinant fungal cell.
  • the production method may especially comprise the culturing method according to the invention.
  • the desired product may be biomass, i.e., the biomass generated by the growth of the recombinant fungal cell.
  • the desired product may be a chemical compound.
  • the desired product may be ethanol.
  • the desired product may be a non-ethanolic fermentation product, especially a bulk or fine chemical, such as a bulk or fine chemical that is producible by a eukaryotic microorganism, especially by the recombinant fungal cell, such as by a recombinant yeast cell or a recombinant filamentous fungus cell.
  • the desired product may comprise a chemical compound selected from the group comprising ethanol, isobutanol, ethene, n-butanol, lactic acid, succinic acid, malic acid, and tetrahymanol, especially selected from the group comprising ethanol, isobutanol, ethene, n-butanol, lactic acid, succinic acid, malic acid, or especially tetrahymanol.
  • the production method may comprise separating a fraction containing the desired product, especially a fraction containing the chemical compound.
  • the parental fungal cell may be auxotrophic for one or more sterols in anoxic conditions.
  • the recombinant fungal cell may grow anaerobically without sterol supplement, thereby enabling the recombinant fungal cell to anaerobically grow in growth media devoid of sterols.
  • These growth media may be cheaper and/or easier to provide than the growth media used for anaerobic growth of the parental fungal cell.
  • the invention may provide a growth medium for anaerobic growth, especially exponential anaerobic growth, of the recombinant fungal cell.
  • the growth medium may comprise nicotinic acid, biotin, pantothenic acid and thiamine.
  • the growth medium may comprise ⁇ 0.5 mg/L of sterols, such as ⁇ 1 mg/L, especially ⁇ 0.1 mg/L, such as ⁇ 0.01 mg/L, including (essentially) no sterols.
  • the invention may provide the use of the recombinant fungal cell to produce a desired product.
  • the use may comprise, especially during at least part of the production, producing the desired product in a growth medium comprising ⁇ 0.1 mg/L dissolved oxygen, , such as ⁇ 0.05 mg/L dissolved oxygen, especially ⁇ 0.01 mg/L dissolved oxygen, such as ⁇ 0.001 mg/L dissolved oxygen, including (essentially) no dissolved oxygen.
  • the growth medium may be anoxic, especially during at least part of the use.
  • Fig. 1A-D schematically depict experimental data obtained using a parental fungal cell and an embodiment of the recombinant fungal cell.
  • Fig. 2A-F schematically depict experimental data obtained using a parental fungal cell and embodiments of the recombinant fungal cell.
  • Fig. 3A-B schematically depict experimental data obtained using a parental fungal cell and an embodiment of the recombinant fungal cell.
  • Fig. 4 schematically depicts experimental data obtained using a parental fungal cell and an embodiment of the recombinant fungal cell.
  • Fig. 5A-C schematically depict experimental data obtained using a parental fungal cell and an embodiment of the recombinant fungal cell.
  • the synthetic medium SMD herein refers to the synthetic medium as described in Verduyn et al. 1992, which is hereby herein incorporated by reference, with 20 g L 1 glucose as carbon source.
  • the synthetic urea medium (SMD-urea) refers to SMD in which ammonium sulfate is replaced by 2.3 g L 1 urea and 6.6 g L 1 K2SO4.
  • the yeast peptone dextrose medium (YPD) refers to a medium comprising 10 g L 1 Bacto yeast extract, 20 g L 1 Bacto peptone and 20 g L 1 glucose.
  • media were supplemented with ergosterol (> 95%, Sigma-Aldrich, St. Louis, MO) as a sterol source and/or Tween 80 (polyethylene glycol sorbate monooleate, Merck, Darmstadt, Germany) as a source of unsaturated fatty acids, to final concentrations of 10 mg L 1 and 420 mg L 1 , respectively.
  • Concentrated stock solutions (800 x) of these supplements were prepared by adding 8.4 g of Tween 80 and/or 0.2 g of ergosterol to 17 mL of absolute ethanol. These suspensions were heated at 80°C for 20 min prior to addition to growth media to ensure proper solubilization of sterols.
  • coli DH5a and derived strains were propagated in Lysogeny Broth (LB, 10 g L 1 Bacto tryptone, 5 g L 1 Bacto yeast extract and 5 g L 1 NaCl), where relevant supplemented with 100 mg L 1 ampicillin. After adding sterile glycerol (30 % v/v), samples were frozen and stored at -80 °C.
  • the synthetic medium SMD-phosphate herein refers to the synthetic medium as described in Verduyn et al. 1992, but with 14.4 g L 1 of potassium dihydrogen phosphate, and with 20 g L 1 glucose.
  • Anaerobic pre-cultures were grown to stationary phase in SMD-urea with Tween 80 and ergosterol and were washed twice with sterile demineralized water and were used to inoculate an anaerobic pre-culture in a shake flask containing SMD- urea with 50 g L 1 glucose and with Tween 80 at an initial OD660 of 0.20.
  • Optical density at 660 nm was measured with a 7200 visible spectrophotometer (Jenway, Staffordshire, UK).
  • the 5-L glass medium reservoir from which the cultures were refilled was kept anoxic by continuous sparging with N5.5 grade N2.
  • Precultures for the SBR experiments - the precultures were prepared by inoculating aerobic shake-flask cultures (100 mL) on SMD containing 20 g L 1 glucose with frozen glycerol stock cultures. After overnight cultivation at 30 °C, a sample from these cultures was used to inoculate a second 100-mL aerobic shake-flask pre-culture on the same medium.
  • Analytical methods - biomass Biomass dry weight measurements were performed using pre-weighed nitrocellulose filters (0.45 pm, Gelman Laboratory, Ann Arbor, MI). Filters were rinsed with demineralized water, used for filtration of 10- or 20-mL culture samples, and washed with demineralized water prior to drying in a microwave oven (20 min at 360 W).
  • GC- FID flame-ionization detection
  • the initial oven temperature was 80 °C and was kept constant for 1 min, then increased to 280 °C at 50 °C min 1 , and finally increased to 320 °C at 6 °C min 1 and kept constant for another 15 min.
  • the inlet temperature was set at 150 °C, and the FID temperature at 280 °C.
  • the GC-FID system was calibrated for squalene (> 98%, Sigma-Aldrich), ergosterol (> 98%, Boom B.V), 5a-cholestane (internal standard; > 97%, Sigma-Aldrich), lanosterol (> 99%, Avanti Polar Lipids, Alabaster AL, United States of America), and tetrahymanol (> 99%, ALB Technologies), using a 10-point calibration curve for all compounds.
  • Examples 1 and 2 relate to experiments wherein the parent fungal cell is a parent S. cerevisiae cell, hereinafter referred to as IMX585, as described (as IMX585) in Mans et al., 2015, which is hereby herein incorporated by reference.
  • IMX585 parent S. cerevisiae cell
  • Example 1 expression of squalene-tetrahymanol cyclase in S. cerevisiae.
  • Example 1 relates to an embodiment of the recombinant fungal cell, wherein the recombinant fungal cell is a recombinant S. cerevisiae cell, hereinafter referred to as IMX1438, derived from IMX585.
  • IMX1438 comprises a genome modification relative to IMX585, wherein the genome modification comprises (an insertion of) an exogenous gene encoding a protein having squalene-tetrahymanol cyclase activity.
  • the exogenous gene hereinafter also referred to as TtTHCl
  • TtTHCl was derived from the squalene-tetrahymanol cyclase gene THC1 of Tetrahymena thermophila (GenBank accession no. XM OO 1026696.2) by codon-optimization for expression in S. cerevisiae using the Jcat algorithm, and corresponds to SEQ ID NO:l.
  • IMX1438 was constructed by inserting an expression cassette comprising TtTHCl into the ri'Crii-locus of IMX585 using Cas9-mediated genome editing with 500 ng of CRISPR plasmid and 400 ng of linear insert.
  • the expression cassette corresponding to SEQ ID NO:3 was integrated between nucleotide positions 172264 and 174002 of chromosome IX of the S. cerevisiae genome (CEN.PK113-7D, NCBI Accession number PRJNA393501, as described in Salazar et al., 2017, which is hereby herein incorporated by reference).
  • the Cas9-mediated genome editing was performed as described in Mans et al., 2015, which is hereby herein incorporated by reference.
  • Example 1 further relates to a further embodiment of the recombinant fungal cell, wherein the recombinant fungal cell is a recombinant S. cerevisiae cell, hereinafter referred to as IMK870, derived from IMX585.
  • IMK870 comprises a genome modification relative to IMX585, wherein the genome modification comprises (an insertion of) an exogenous gene encoding a protein having squalene-tetrahymanol cyclase activity, and wherein the genome modification further comprises a deletion of a squalene epoxidase gene.
  • IMK870 was constructed using the same procedure as outlined hereabove for IMX1438, followed by a deletion of the ERG1 gene (encoding squalene epoxidase).
  • the ERG1 gene was deleted by inserting an expression cassette corresponding to SEQ ID NO: 5 between nucleotide positions 872978 and 874956 of chromosome VII of the S. cerevisiae genome (CEN.PK113- 7D, NCBI Accession number PRJNA393501, as described in Salazar et al., 2017).
  • the inserted expression cassette comprised a KanMX gene under control of the TEFL -promotor and TEFL -terminator (AgTEFlp-KanMX-AgTEFlt) as a marker to select the recombinant cells.
  • S. cerevisiae strains used in example 1 are:
  • Fig. 1A-D schematically depict experimental data obtained using IMX585 and IMX1438 in growth media supplemented with ergosterol.
  • Fig. 1A-D depict CO2 percentage P (%C0 2 in off-gas; Fig. 1A, Fig. 1C), and measurement values of biomass B (in g/L) and compounds C (in g/L; Fig. IB, Fig. ID) over time (in hours) for IMX585 (Fig. 1A, Fig. IB) and IMX1438 (Fig. 1C, Fig. ID).
  • Fig. 1A-D each represent data from a single representative experiment of three anaerobic sequential batch reactor (SBR) experiments (see above) at 30°C on SMD-urea.
  • SBR sequential batch reactor
  • Fig. 1A, Fig. 1C indicate the CO 2 percentage P during a carry-over phase on medium without anaerobic growth factors (Bo) and the first (Bi), second (B 2 ) and third (B 3 ) batch cycles on growth medium supplemented with Tween 80 and ergosterol.
  • the phrase “without anaerobic growth factors” herein refers to the absence of unsaturated fatty acids, including Tween 80, as well as to the absence of sterols, including ergosterol.
  • Fig. IB, Fig. ID indicate measurement values of biomass B and compounds C during the second batch cycle, wherein line Li represents biomass, line L2 represents glucose, line L3 represents ethanol, and line L4 represents glycerol.
  • both the recombinant fungal cell and the parental fungal cell were observed to exhibit exponential growth in anoxic conditions in a growth medium supplemented with ergosterol.
  • Fig. 2A-F schematically depict experimental data obtained using IMX585, IMX1438 and IMK870 in growth media without ergosterol.
  • Fig. 2A-F depict CO2 percentage P (%C0 2 in off-gas; Fig. 2A, Fig. 2C; Fig. 2E), and measurement values of biomass B (in g/L) and compounds C (in g/L; Fig. 2B, Fig. 2D; Fig. 2F) over time (in hours) for IMX585 (Fig. 2 A, Fig. 2B), IMX1438 (Fig. 2C, Fig. 2D), and IMK870 (Fig. 2E, Fig. 2F).
  • Fig. 2A-F each represent data from a single representative experiment of three anaerobic sequential batch reactor (SBR) experiments (see above) at 30°C on SMD-urea.
  • SBR sequential batch reactor
  • Fig. 2A, Fig. 2C, Fig. 2E indicate the CO2 percentage P during a carry-over phase on medium without anaerobic growth factors (Bo) and the first (Bi), second (B2) and third (B3) batch cycles on growth medium supplemented with Tween 80.
  • Fig. 2B, Fig. 2D, Fig. 2F indicate measurement values of biomass B and compounds C during the second batch cycle, wherein line Li represents biomass, line L2 represents glucose, line L3 represents ethanol, and line L4 represents glycerol.
  • IMX585 was not observed to grow exponentially in the absence of sterol supplementation. Although IMX585 was observed to eventually consume all glucose, this took approximately 100 hours (see Fig. 2B). In contrast, IMX1438 and IMK870 were observed to grow exponentially and to consume the glucose in approximately 35 and 50 hours respectively.
  • IMX585, IMX1438, and IMK870 were grown anaerobically on glucose synthetic medium with Tween 80, in presence or absence of ergosterol.
  • the observed specific growth rates and biomass yields are provided in the table below, represented as average values and standard deviations based on at least two replicate experiments: Hence, the expression of a gene encoding a protein having squalene- tetrahymanol cyclase activity is observed to enable a recombinant fungal cell to anaerobically grow (exponentially) in the absence of sterol supplementation.
  • Lanosterol may be the first cyclic compound after epoxidation of squalene in the natural ergosterol synthesis pathway in S. cerevisiae and the synthesis thereof may require molecular oxygen.
  • the presence of lanosterol may imply the presence of some residual molecular oxygen, which may account for the observed biomass increase depicted in Fig. 2B.
  • IMK870 no lanosterol was observed, consistent with the deletion of the squalene epoxidase gene ( ERG1 ) in IMK870.
  • ERG1 squalene epoxidase gene
  • Example 2 expression of squalene-hopene cyclase in S. cerevisiae.
  • Example 2 relates to an embodiment of the recombinant fungal cell, wherein the recombinant fungal cell is a recombinant S. cerevisiae cell, hereinafter referred to as IMX2081, derived from IMX585.
  • IMX2081 comprises a genome modification relative to IMX585, wherein the genome modification comprises (an insertion of) an exogenous gene encoding a protein having squalene-hopene cyclase activity.
  • the exogenous gene hereinafter also referred to as SjSHC
  • SjSHC was derived from the squalene-hopene cyclase gene SHC of Schizosaccharomyces japonicus yFS275 (Genbank Accession number: NW_011627861.1) by codon-optimization for use in S. cerevisiae using the online GeneOptimizer tool (GeneArt, Regensburg, Germany), and corresponds to SEQ ID NO:2.
  • IMX2081 was constructed by inserting the exogenous gene under control of the TEFL -promoter and with the CYC1- terminator into the SGA /-locus of IMX585 using Cas9-mediated genome editing.
  • the expression cassette corresponding to SEQ ID NO:4 was integrated between nucleotide positions 172264 and 173934 of chromosome IX of the S. cerevisiae genome (CEN.PK113- 7D, NCBI Accession number PRJNA393501, as described in Salazar et al., 2017).
  • the use of the TEFL -promoter (also “ZE ”) and the CTC7 -terminator for expression in yeast is described in Ronicke et al, 1997, which is hereby herein incorporated by reference.
  • the Cas9-mediated genome editing was performed as described in Mans et al., 2015.
  • S. cerevisiae strains used in example 2 are:
  • IMX585 and IMX2081 were grown aerobically overnight on SMD-urea. From this pre-culture, strains were transferred to fresh SMD-urea in the anaerobic chamber (carry over), for depletion of the internal sterol storage. The carry-over medium contained 50 g.L 1 glucose. When stationary phase was reached, the cultures were transferred to SMD-urea containing Tween 80 and ergosterol (T/E), Tween 80 only (T/-), or neither Tween 80 nor ergosterol (-/-).
  • Fig. 3A-B schematically depicts the O ⁇ boo (O) of IMX585 (Fig. 3A) and IMX2081 (Fig. 3B) over time (in hours) in the carry-over medium, T/E, T /-, and -/-, wherein line Lii represents the observations from the carry-over medium, line L12 from T/E, line L13 from T /-, and line Lu from -/-.
  • both IMX585 and IMX2081 were observed to grow anaerobically in SMD-urea supplemented with both Tween 80 and ergosterol.
  • Tween 80 When supplied with Tween 80 only, minimal background growth was observed for the parental fungal cell IMX585, while the recombinant fungal cell IMX2081 harboring the SjSHC gene showed clear anaerobic growth.
  • IMX2081 was observed to grow anaerobically, whereas the parental strain IMX585 was not.
  • Example 3 expression of squalene-tetrahymanol cyclase in K. marxianus.
  • Example 3 relates to an embodiment of the recombinant fungal cell, wherein the recombinant fungal cell is a recombinant K. marxianus cell, hereinafter referred to as IMS1111, derived from K. marxianus NBRC 1777, hereinafter referred to as NBRC 1777.
  • IMS1111 derived from K. marxianus NBRC 1777, hereinafter referred to as NBRC 1777.
  • NBRC 1777 was ordered from the Biological Resource Center, NITE (NBRC) (Chiba, Japan).
  • IMS1111 comprises a genome modification relative to NBRC1777, wherein the genome modification comprises (an insertion of) an exogenous gene encoding a protein having squalene-tetrahymanol cyclase activity.
  • TtTHCl the exogenous gene, hereinafter also referred to as TtTHCl , was derived from the squalene-tetrahymanol cyclase gene THC1 of Tetrahymena thermophila (GenBank accession no. XM_001026696.2) by codon-optimization for expression in S. cerevisiae using the Jcat algorithm, and corresponds to SEQ ID NO:l.
  • recombinant fungal cell IMX2323 was constructed by transforming NBRC1777, using the LiAc procedure described by Gietz and Woods (2002), which is hereby herein incorporated by reference, with a Notl digested linear DNA fragment of an expression cassette comprising TtSHCl and transformants were selected on YPD-hygB plates (YPD plates with added hygromycin B as selective marker) for integration of SHCl.
  • the use of the KmPDCl -promoter and the ScADHl terminator is described in Rajkumar et al, 2019 and Hassing el al, 2019, respectively, which are hereby herein incorporated by reference.
  • IMX2323 was incubated in SMD-urea supplemented with Tween-80 in micro-oxic conditions. When, after 20 days of incubation, growth was observed, two transfers to fresh SMD-urea medium with Tween-80 were performed. Then, a single cell line was isolated by plating on three consecutive YPD agar plates containing hygromycin B. After the final restreak, this procedure yielded the single-colony isolate recombinant fungal cell IMS 1111.
  • K. marxianus strains used in example 3 are:
  • Fig. 4 schematically depicts observed OD600 over time (in hours) of 5 serial transfers on SMD-urea of the K. marxianus parental strain and the recombinant fungal cell strains. Specifically, lines L21 represents IMS1111, lines L22 represents NBRC1777, and lines L23 represents IMX2323.
  • Tetrahymanol was detected in biomass of anaerobically cultivated IMS1111 in each of the sequential transfers, indicating the successful expression of the inserted exogenous gene.
  • K. marxianm including strain NBRC1777
  • the insertion of the exogenous gene encoding a protein having squalene-tetrahymanol cyclase activity enabled the recombinant K. marxianm cell to acquire the ability to grow (exponentially) in anoxic conditions.
  • Example 4 expression of squalene-hopene cyclase and tetrahymanol synthase in S. cerevisiae.
  • Example 4 relates to an embodiment of the recombinant fungal cell, wherein the recombinant fungal cell is a recombinant S. cerevisiae cell, hereinafter referred to as IMX2616, derived from IMX2600.
  • IMX2616 a recombinant S. cerevisiae cell
  • Example 4 further relates to an embodiment of the recombinant fungal cell, wherein the recombinant fungal cell is a recombinant S. cerevisiae cell, hereinafter referred to as IMX2629, derived from IMX2616.
  • IMX2629 a recombinant S. cerevisiae cell
  • Strain IMX2600 was constructed by integration of cas9 and natNT2 expression cassettes in the CAN1 locus of CEN.PK113-7D.
  • the integration/expression cassettes for cas9 and natNT2 were respectively obtained by PCR from p414-TEFlp-cas9-CYCl as described in Dicarlo et al., 2013 and pUG-natNT2 as described in Stefan de Kok et ak, 2012.
  • Strain IMX2616 ( MATa canl A::cas9-natNT2 sgal AwSjSHC) was constructed by genomic integration of an expression cassette for a codon-optimized squalene-hopene cyclase gene from Schizosaccharomyces japonicus CBS5679 in strain IMX2600.
  • Strain IMX2629 ( MATa canl A: ⁇ cas9-natNT2 sgal A: ⁇ SjSHC x2 A: ⁇ MaTHS) was constructed by subsequent genomic integration of an expression cassette for a codon-optimized tetrahymanol synthase gene MaTHS from Methylomicrobium alkaliphilum (Genbank Accession number: F0082060.1, locus tag MEALZ_1626) in strain IMX2629.
  • IMX2616 comprises a genome modification relative to IMX2600, wherein the genome modification comprises (an insertion of) an exogenous gene encoding a protein having squalene-hopene cyclase activity.
  • the exogenous gene hereinafter also referred to as SjSHC 2
  • SjSHC 2 was derived from the squalene-hopene cyclase gene SHC of Schizosaccharomyces japonicus CBS5679 by codon-optimization for expression in S. cerevisiae using the GeneOptimizer tool, and corresponds to SEQ ID NO:7.
  • IMX2616 was constructed by inserting an expression cassette comprising SjSHC 2 under control of the TEF1 promotor and the CYC1 terminator into the ri'Grif-locus of IMX2600.
  • the expression cassette was inserted by co-transformation with ri'GVI /-targeting plasmid pUDRl 19 as described in Van Rossum et al, 2016.
  • the expression cassette corresponding to SEQ ID NO:9 was integrated between nucleotide positions 172264 and 173934 of chromosome IX of the S. cerevisiae genome (CEN.PK113-7D, also see above).
  • Example 4 further relates to a further embodiment of the recombinant fungal cell, wherein the recombinant fungal cell is a recombinant S. cerevisiae cell, hereinafter referred to as IMX2629, derived from IMX2616.
  • IMX2629 comprises a genome modification relative to IMX2616, wherein the genome modification comprises (an insertion of) an exogenous gene encoding a protein having tetrahymanol synthase activity.
  • IMX2629 comprises a genome modification relative to IMX2600, wherein the genome modification comprises (the insertion of) a plurality of exogenous genes, wherein a (second) exogeneous gene encodes a protein having squalene- hopene cyclase activity, and wherein a (third) exogeneous gene a protein having tetrahymanol synthase activity.
  • the exogenous gene hereinafter also referred to as MaTHS, was derived from the tetrahymanol synthase gene THS of Methylomicrobium alcaliphilum 20Z (GenBank accession no.
  • IMX2629 was constructed by inserting an expression cassette comprising MaTHS under control of the TDH3 promotor and the ADH1 terminator into the X2 -locus of IMX2616 by co-transformation with X2-targeting plasmid pUDR538.
  • the expression cassette corresponding to SEQ ID NO: 10. was integrated between nucleotide positions 194944 and 195980 of chromosome X of the S.
  • CEN.PK113-7D cerevisiae genome (CEN.PK113-7D, as represented on SGD (http s : //www. y eastgenome . or g/) ; also corresponding to the X2-locus as described by Mikkelsen et al.,).
  • S. cerevisiae strains used in example 4 are:
  • Aerobically grown cultures of these strains were used to inoculate an anaerobic pre-culture on SMD-phosphate with a higher glucose concentration (50 g L 1 ).
  • the pre-cultures were grown until end- exponential phase to stimulate depletion of sterols originating from the preceding aerobic culture.
  • These pre-cultures were used to inoculate fresh SMD-phosphate medium (with 20 g L 1 glucose) in the absence of an exogenous source of unsaturated fatty acids or sterols, and SMD-phosphate medium to which only Tween 80 was added.
  • Fig. 5A-C schematically depict the corresponding O ⁇ boo measurements over time T (in hours) with two biological duplicates, where Fig.
  • Fig. 5A corresponds to parental fungal cell CEN.PK113-7D
  • Fig. 5B corresponds to IMX2616
  • Fig. 5C corresponds to IMX2929.
  • the open circles lines L52, L55, and L58
  • the filled circles correspond to cultivation media supplemented with Tween 80.
  • CEN.PK113-7D reached an optical density of 1.1 in 58 h (see L51), while strains IMX2616 and IMX2629 reached OD 6 oo’s of 2.1 and 2.4 in 33 hours, respectively (see L54 and L56).
  • both recombinant strains sustained growth for another 2.8 doublings (see lines L54 and L57).
  • CEN.PK113-7D grown on medium with Tween 80 was not able to consume its glucose
  • residual glucose was low for IMX2629. Specifically, residual glucose was 1.08 ⁇ 1.02 mM and 0.09 ⁇ 0.09 mM vs. 35.54 ⁇ 1.68 mM after 42 for IMX2616, IMX2629 and after 58 hours for CEN.PK113-7D, respectively.
  • the biomass of IMX2616 and IMX2629 contained multiple additional triterpenoid compounds with reference to strain CEN.PK113-7D, of which one could be identified as hop-22(29)-ene (diploptene) based on synthetic reference material.
  • the biomass of strain IMX2629 additionally contained tetrahymanol.
  • the terms “substantially” or “essentially” herein, and similar terms, will be understood by the person skilled in the art.
  • the terms “substantially” or “essentially” may also include embodiments with “entirely”, “completely”, “all”, etc. Hence, in embodiments the adjective substantially or essentially may also be removed.
  • the term “substantially” or the term “essentially” may also relate to 90% or higher, such as 95% or higher, especially 99% or higher, even more especially 99.5% or higher, including 100%.
  • the terms ’’about” and “approximately” may also relate to 90% or higher, such as 95% or higher, especially 99% or higher, even more especially 99.5% or higher, including 100%.
  • a phrase “item 1 and/or item 2” and similar phrases may relate to one or more of item 1 and item 2.
  • the term “comprising” may in an embodiment refer to "consisting of but may in another embodiment also refer to "containing at least the defined species and optionally one or more other species”.
  • the invention may be implemented by means of hardware comprising several distinct elements, and by means of a suitably programmed computer.
  • a device claim, or an apparatus claim, or a system claim enumerating several means, several of these means may be embodied by one and the same item of hardware.
  • the mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage.
  • the invention also provides a control system that may control the device, apparatus, or system, or that may execute the herein described method or process. Yet further, the invention also provides a computer program product, when running on a computer which is functionally coupled to or comprised by the device, apparatus, or system, controls one or more controllable elements of such device, apparatus, or system.
  • the invention further applies to a device, apparatus, or system comprising one or more of the characterizing features described in the description and/or shown in the attached drawings.
  • the invention further pertains to a method or process comprising one or more of the characterizing features described in the description and/or shown in the attached drawings.
  • a method or an embodiment of the method is described being executed in a device, apparatus, or system, it will be understood that the device, apparatus, or system is suitable for or configured for (executing) the method or the embodiment of the method respectively.
  • Hassing et al “Connecting central carbon and aromatic amino acid metabolisms to improve de novo 2-phenylethanol production in Saccharomyces cerevisiae”, 2019, Metab Eng;56: 165-80.
  • CRISPR/Cas9 a molecular Swiss army knife for simultaneous introduction of multiple genetic modifications in Saccharomyces cerevisiae ”, 2015, FEMS Yeast Research, volume 15, pages 1-15

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une cellule fongique recombinée comprenant au moins une modification de génome par rapport à une cellule fongique parentale, la modification du génome comprenant un gène exogène codant pour une protéine choisie dans le groupe comprenant une protéine ayant une activité de squalène-tétrahymanol cyclase et une protéine ayant une activité de squalène-hopène cyclase, la cellule fongique recombinante étant une cellule de levure choisie dans le groupe constitué par Saccharomyces et Kluyveromyces.
PCT/NL2020/050818 2019-12-24 2020-12-24 Cellule fongique recombinante WO2021133171A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NL2024578 2019-12-24
NL2024578A NL2024578B1 (en) 2019-12-24 2019-12-24 Recombinant fungal cell
NL2024886 2020-02-12
NL2024886 2020-02-12

Publications (1)

Publication Number Publication Date
WO2021133171A1 true WO2021133171A1 (fr) 2021-07-01

Family

ID=74104153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2020/050818 WO2021133171A1 (fr) 2019-12-24 2020-12-24 Cellule fongique recombinante

Country Status (1)

Country Link
WO (1) WO2021133171A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023052336A1 (fr) 2021-09-28 2023-04-06 Apix Biosciences Procédés d'administration de cholestérol 24-méthylène, d'isofucostérol, de cholestérol ou de desmostérol à des invertébrés, en particulier des abeilles mellifères ou des bourdons
WO2023052339A1 (fr) 2021-09-28 2023-04-06 Apix Biosciences Procédés d'administration de nutriments bénéfiques à des invertébrés par l'intermédiaire d'un micro-organisme déficient en anti-nutriments
WO2023057041A1 (fr) 2021-10-04 2023-04-13 Apix Biosciences Procédés d'administration de cholestérol 24-méthylène, d'isofucostérol, de cholestérol ou de desmostérol à des invertébrés, en particulier des abeilles mellifères ou des bourdons
WO2023089317A1 (fr) 2021-11-19 2023-05-25 Oxford University Innovation Limited Production de stérol dans de la levure
CN116396986A (zh) * 2023-06-01 2023-07-07 中义(北京)健康研究院 一种乳酸克鲁维酵母菌在生产角鲨烯中的应用
WO2023227815A1 (fr) * 2022-05-24 2023-11-30 Universitat Politècnica De València Levure et plasmide pour l'exposition de protéines en surface

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207317A1 (en) 1999-12-01 2003-11-06 Matthias Rusing Novel nucleic acid isolated from Tetrahymena which codes for a triterpenoid cyclase, its production, and use
EP3042960A1 (fr) 2013-09-05 2016-07-13 Niigata University Procédé de preparation d'ambreine
WO2018114973A1 (fr) * 2016-12-20 2018-06-28 Novozymes A/S Souches de levures recombinées pour la fermentation du pentose
WO2018157021A1 (fr) 2017-02-24 2018-08-30 International Flavors & Fragrances Inc. Squalène hopène cyclase et son utilisation pour la production d'ambroxan
WO2019149789A1 (fr) * 2018-02-01 2019-08-08 Dsm Ip Assets B.V. Cellule de levure capable de fermenter simultanément des sucres hexose et pentose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207317A1 (en) 1999-12-01 2003-11-06 Matthias Rusing Novel nucleic acid isolated from Tetrahymena which codes for a triterpenoid cyclase, its production, and use
EP3042960A1 (fr) 2013-09-05 2016-07-13 Niigata University Procédé de preparation d'ambreine
WO2018114973A1 (fr) * 2016-12-20 2018-06-28 Novozymes A/S Souches de levures recombinées pour la fermentation du pentose
WO2018157021A1 (fr) 2017-02-24 2018-08-30 International Flavors & Fragrances Inc. Squalène hopène cyclase et son utilisation pour la production d'ambroxan
WO2019149789A1 (fr) * 2018-02-01 2019-08-08 Dsm Ip Assets B.V. Cellule de levure capable de fermenter simultanément des sucres hexose et pentose

Non-Patent Citations (39)

* Cited by examiner, † Cited by third party
Title
"Genbank", Database accession no. NW-011627861.1
"GenBank", Database accession no. XM 001026696.2
"NCBI", Database accession no. PRJNA393501
BANTA A. B. ET AL: "A distinct pathway for tetrahymanol synthesis in bacteria", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 44, 19 October 2015 (2015-10-19), US, pages 13478 - 13483, XP055782909, ISSN: 0027-8424, DOI: 10.1073/pnas.1511482112 *
CAMPBELL I. ET AL: "GROWTH OF AEROBIC WILD YEASTS", JOURNAL OF THE INSTITUTE OF BREWING., vol. 97, no. 4, 8 July 1991 (1991-07-08), GB, pages 279 - 282, XP055722088, ISSN: 0046-9750, DOI: 10.1002/j.2050-0416.1991.tb01069.x *
CAMPBELLMSONGO: "GROWTH OF AEROBIC WILD YEASTS", JOURNAL OF THE INSTITUTE OF BREWING, 1991
DA COSTA B. L. V. ET AL: "Forever panting and forever growing: physiology of Saccharomyces cerevisiae at extremely low oxygen availability in the absence of ergosterol and unsaturated fatty acids", FEMS YEAST RESEARCH, vol. 19, no. 6, FOZ054, 19 August 2019 (2019-08-19), pages 1-14, XP009522206, ISSN: 1567-1356, DOI: 10.1093/FEMSYR/FOZ054 *
DE KOK ET AL.: "Laboratory evolution of new lactate transporter genes in a jenlA mutant of Saccharomyces cerevisiae and their identification as ADY2 alleles by whole-genome resequencing and transcriptome analysis", FEMS YEAST RESEARCH, vol. 12, 2012, pages 359 - 374
DEKKER ET AL.: "Anaerobic growth of Saccharomyces cerevisiae CEN.PK113-7D does not depend on synthesis or supplementation of unsaturated fatty acids", FEMS YEAST RESEARCH, vol. 19, September 2019 (2019-09-01)
DEKKER W. J. C. ET AL: "Anaerobic growth of Saccharomyces cerevisiae CEN.PK113-7D does not depend on synthesis or supplementation of unsaturated fatty acids", FEMS YEAST RESEARCH, vol. 19, no. 6, FOZ060, 19 August 2019 (2019-08-19), GB, NL, pages 1 - 10, XP055722078, ISSN: 1567-1356, DOI: 10.1093/femsyr/foz060 *
DICARLO ET AL.: "Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems", NUCLEIC ACIDS RESEARCH, vol. 41, no. 7, 2013, XP055604254, DOI: 10.1093/nar/gkt135
DUMITRU ET AL.: "Defined Anaerobic Growth Medium for Studying Candida albicans Basic Biology and Resistance to Eight Antifungal Drugs", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004
DUMITRU R. ET AL: "Defined Anaerobic Growth Medium for Studying Candida albicans Basic Biology and Resistance to Eight Antifungal Drugs", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 48, no. 7, 23 June 2004 (2004-06-23), US, pages 2350 - 2354, XP055335684, ISSN: 0066-4804, DOI: 10.1128/AAC.48.7.2350-2354.2004 *
GIETZWOODS: "Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method", METHODS IN ENZYMOLOGY, vol. 350, 2002, pages 87 - 96, XP008068319
HASSING ET AL.: "Connecting central carbon and aromatic amino acid metabolisms to improve de novo 2-phenylethanol production in Saccharomyces cerevisiae", METAB ENG, vol. 56, 2019, pages 165 - 80, XP085876206, DOI: 10.1016/j.ymben.2019.09.011
HOSHINO T. ET AL: "Squalene-hopene cyclase: catalytic mechanism and substrate recognition", CHEMICAL COMMUNICATIONS, no. 4, 17 January 2002 (2002-01-17), pages 291 - 301, XP055533113, ISSN: 1359-7345, DOI: 10.1039/b108995c *
HUSEYIN C. E. ET AL: "The Fungal Frontier: A Comparative Analysis of Methods Used in the Study of the Human Gut Mycobiome", FRONTIERS IN MICROBIOLOGY, vol. 8, 1432, 31 July 2017 (2017-07-31), pages 1 - 15, XP055723120, DOI: 10.3389/fmicb.2017.01432 *
HUSEYIN ET AL.: "The Fungal Frontier: A Comparative Analysis of Methods Used in the Study of the Human Gut Mycobiome", FRONTIERS IN MICROBIOLOGY, 2017
LABATE VALDE DA COSTA ET AL.: "Forever panting and forever growing: physiology of Saccharomyces cerevisiae at extremely low oxygen availability in the absence of ergosterol and unsaturated fatty acids", FEMS YEAST RESEARCH, vol. 19, September 2019 (2019-09-01)
LORENZ ET AL.: "Structural Discrimination in the Sparking Function of Sterols in the Yeast Saccharomyces cerevisiae", JOURNAL OF BACTERIOLOGY, vol. 171, no. 11, 1989, pages 6169 - 6173
MACY J. M. ET AL: "ANAEROBIC GROWTH OF SACCHAROMYCES-CEREVISIAE IN THE ABSENCE OF OLEIC-ACID AND ERGOSTEROL?", ARCHIVES OF MICROBIOLOGYERG, vol. 134, no. 1, 1983, pages 64 - 67, XP009522255, ISSN: 0302-8933, DOI: 10.1007/BF00429409 *
MACYMILLER: "Anaerobic growth of Saccharomyces cerevisiae in the absence of oleic acid and ergosterol?", ARCHIVES OF MICROBIOLOGY, vol. 134, 1983, pages 64 - 67, XP009522255, DOI: 10.1007/BF00429409
MANS ET AL.: "CRISPR/Cas9: a molecular Swiss army knife for simultaneous introduction of multiple genetic modifications in Saccharomyces cerevisiae", FEMS YEAST RESEARCH, vol. 15, 2015, pages 1 - 15, XP002762726
MIKKELSEN ET AL.: "Microbial production of indolylglucosinolate through engineering of a multi-gene pathway in a versatile yeast expression platform", METABOLIC ENGINEERING, vol. 14, 2012, pages 104 - 111, XP028466090, DOI: 10.1016/j.ymben.2012.01.006
MULLER ET AL.: "Antifungal drug testing by combining minimal inhibitory concentration testing with target identification by gas chromatography-mass spectrometry", NATURE PROTOCOLS, vol. 12, 2017, pages 947 - 963
NES ET AL.: "The Structural Requirements of Sterols for Membrane Function in Saccharomyces cerevisiae", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 300, no. 2, 1993, pages 723 - 733, XP024753418, DOI: 10.1006/abbi.1993.1100
PINTONES: "Stereochemical Specificity for Sterols in Saccharomyces cerevisiae", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 258, no. 7, 1983, pages 4472 - 4476
RAJKUMAR ET AL.: "Biological Parts for Kluyveromyces marxianus Synthetic Biology", FRONT BIOENG BIOTECHNOL, vol. 7, 2019, pages 1 - 15
REIPEN I. G. ET AL: "Zymomonas mobilis squalene-hopene cyclase gene (shc): cloning, DNA sequence analysis and expression in escherichia coli", JOURNAL OF GENERAL MICROBIOLOGY, vol. 141, no. 1, 1 January 1995 (1995-01-01), pages 155 - 161, XP002969317, ISSN: 1350-0872 *
RODRIGUEZ RJ ET AL.: "A requirement for ergosterol to permit growth of yeast sterol auxotrophs on cholestanol", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 106, 1982, pages 435 - 441, XP024839001, DOI: 10.1016/0006-291X(82)91129-9
RONICKE ET AL.: "Use of conditional promoters for expression of heterologous proteins in Saccharomyces cerevisiae", METHODS IN ENZYMOLOGY, vol. 283, 1997, pages 313 - 322
SAAR J. ET AL: "Purification and some properties of the squalene-tetrahymanol cyclase from Tetrahymena thermophila", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - GENERAL SUBJECTS, vol. 1075, no. 1, 2 September 1991 (1991-09-02), pages 93 - 101, XP023577166, ISSN: 0304-4165, [retrieved on 19910902], DOI: 10.1016/0304-4165(91)90080-Z *
SALAZAR ET AL.: "Nanopore sequencing enables near-complete de novo assembly of Saccharomyces cerevisiae reference strain CEN.PK113-7D", FEMS YEAST RES, vol. 17, 2017, pages fox074
SNOEKSTEENSMA: "Factors involved in anaerobic growth of Saccharomyces cerevisiae", YEAST, vol. 24, 2007, pages 1 - 10
TAKISHITA K. ET AL: "Lateral transfer of tetrahymanol-synthesizing genes has allowed multiple diverse eukaryote lineages to independently adapt to environments without oxygen", BIOLOGY DIRECT, vol. 7, 5, 1 February 2012 (2012-02-01), pages 1 - 7, XP021123867, ISSN: 1745-6150, DOI: 10.1186/1745-6150-7-5 *
VAN ROSSUM ET AL.: "Alternative reactions at the interface of glycolysis and citric acid cycle in Saccharomyces cerevisiae", FEMS YEAST RESEARCH, vol. 16, 2016
VERDUYN ET AL.: "Effect of Benzoic Acid on Metabolic Fluxes in Yeasts: A Continuous-Culture Study on the Regulation of Respiration and Alcoholic Fermentation", YEAST, vol. 8, 1992, pages 501 - 517, XP008082716, DOI: 10.1002/yea.320080703
WELANDER P. V. ET AL: "Deciphering the evolutionary history of microbial cyclic triterpenoids", FREE RADICAL BIOLOGY & MEDICINE, vol. 140, 6 May 2019 (2019-05-06), pages 270 - 278, XP085826544, ISSN: 0891-5849, [retrieved on 20190506], DOI: 10.1016/J.FREERADBIOMED.2019.05.002 *
WIERSMA S J. ET AL: "Expression of a squalene-tetrahymanol cyclase enables sterol-independent growth of Saccharomyces cerevisiae", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 19 June 2020 (2020-06-19), US, pages 1 - 43, XP055722145, ISSN: 0099-2240, DOI: 10.1128/AEM.00672-20 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023052336A1 (fr) 2021-09-28 2023-04-06 Apix Biosciences Procédés d'administration de cholestérol 24-méthylène, d'isofucostérol, de cholestérol ou de desmostérol à des invertébrés, en particulier des abeilles mellifères ou des bourdons
WO2023052339A1 (fr) 2021-09-28 2023-04-06 Apix Biosciences Procédés d'administration de nutriments bénéfiques à des invertébrés par l'intermédiaire d'un micro-organisme déficient en anti-nutriments
WO2023057041A1 (fr) 2021-10-04 2023-04-13 Apix Biosciences Procédés d'administration de cholestérol 24-méthylène, d'isofucostérol, de cholestérol ou de desmostérol à des invertébrés, en particulier des abeilles mellifères ou des bourdons
WO2023089317A1 (fr) 2021-11-19 2023-05-25 Oxford University Innovation Limited Production de stérol dans de la levure
WO2023227815A1 (fr) * 2022-05-24 2023-11-30 Universitat Politècnica De València Levure et plasmide pour l'exposition de protéines en surface
CN116396986A (zh) * 2023-06-01 2023-07-07 中义(北京)健康研究院 一种乳酸克鲁维酵母菌在生产角鲨烯中的应用
CN116396986B (zh) * 2023-06-01 2023-08-29 中义(北京)健康研究院 一种乳酸克鲁维酵母菌在生产角鲨烯中的应用

Similar Documents

Publication Publication Date Title
WO2021133171A1 (fr) Cellule fongique recombinante
Cernak et al. Engineering Kluyveromyces marxianus as a robust synthetic biology platform host
US11186850B2 (en) Recombinant yeast cell
EP2576605B1 (fr) Production de métabolites
CN105189731A (zh) 制备脂肪二羧酸的生物学方法
CN110268057B (zh) 用于鉴定和表达基因簇的系统和方法
US9885065B2 (en) Methods for succinate production
CN105121624A (zh) 制备脂肪二羧酸的生物学方法
US10301655B2 (en) Method for producing acetoin
Liu et al. Engineered ethanol-driven biosynthetic system for improving production of acetyl-CoA derived drugs in Crabtree-negative yeast
Cao et al. Metabolic engineering of oleaginous yeast Rhodotorula toruloides for overproduction of triacetic acid lactone
US11795464B2 (en) Inducible production-phase promoters for coordinated heterologous expression in yeast
US20180187204A1 (en) Combination of bacterial chaperones positively affecting the physiology of a native or engineered eukaryotic cell
Mitsui et al. Saccharomyces cerevisiae as a microbial cell factory
NL2024578B1 (en) Recombinant fungal cell
JP6343754B2 (ja) 耐酸耐塩性付与方法と耐酸耐塩性酵母を用いた有用物質生産
CA2956189C (fr) Souches de micro-organismes pour la production de 2,3-butanediol
Cernak et al. Engineering Kluyveromyces marxianus as a robust synthetic biology platform host. mBio 9: e01410-18
WO2019110491A1 (fr) Cellule de levure recombinée
US20230272364A1 (en) Gluconate dehydratase enzymes and recombinant cells
EP3469067B1 (fr) Cellule de levure de recombinaison
Schwartz Development and Application of Advanced Synthetic Biology Tools for Engineering Chemical Production in Yarrowia lipolytica
Loebs Understanding and Engineering Ester Biosynthesis Pathways in the Yeast Kluyveromyces marxianus
Peri et al. Regulation of lactose and galactose growth: Insights from a unique metabolic gene cluster in Candida intermedia
Estrela Curado Domestication and engineering of the yeast Kluyveromyces marxianus, a favored industrial host

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20830382

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20830382

Country of ref document: EP

Kind code of ref document: A1